4118 Clofarabine: safety and efficacy profile for treatment of pediatric patients with refractory or relapsed acute leukemias

K.Kleinschmidt; A.Martoni; R.Masetti; F.Melchionda; A.Prete; A.Pession

首页> 外文期刊>European Journal of Cancer Supplements >4118 Clofarabine: safety and efficacy profile for treatment of pediatric patients with refractory or relapsed acute leukemias

【24h】

4118 Clofarabine: safety and efficacy profile for treatment of pediatric patients with refractory or relapsed acute leukemias

机译：4118氯法拉滨：治疗难治性或复发性急性白血病的小儿患者的安全性和有效性

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共2页
作者
K.Kleinschmidt; A.Martoni; R.Masetti; F.Melchionda; A.Prete; A.Pession;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy, safety and pharmacokinetics of clofarabine in Chinese pediatric patients with refractory or relapsed acute lymphoblastic leukemia: a phase II, multi-center study [J] . A Lu, Y Fang, X Du, Blood cancer journal. . 2016,第2期

机译：氯法拉滨在中国小儿难治性或复发性急性淋巴细胞性白血病患者中的疗效，安全性和药代动力学：II期，多中心研究
2. Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes [J] . Roberts Daniel A., Wadleigh Martha, McDonnell Anne M., Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis . 2015,第2期

机译：氯法拉滨治疗复发/难治性急性髓细胞性白血病和骨髓增生异常综合征相关的低效率和高死亡率
3. Experience with Clofarabine use in Refractory/Relapsed Acute Leukemia Pediatric Patients at the Instituto Nacional De Enfermedades Neoplasicas (INEN), LIMA - PERU [J] . Garcia J. L. Pediatric blood & cancer . 2017,第Suppla3期

机译：在Instituto Nacional de Enfermedadesnooplasicas（Inen），利马 - 秘鲁的耐火感染/复发急性白血病儿科患者的使用经验
4. Computationally derived cytological image markers for predicting risk of relapse in acute myeloid leukemia patients following bone marrow transplantation [C] . Sara ArabYarmohammadi, Zelin Zhang, Patrick Leo, Conference on Medical Imaging: Digital Pathology . 2020

机译：计算源自骨髓移植后急性髓性白血病患者复发风险的细胞学图像标志物
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Efficacy safety and pharmacokinetics of clofarabine in Chinese pediatric patients with refractory or relapsed acute lymphoblastic leukemia: a phase II multi-center study [O] . A Lu, Y Fang, X Du, 2016

机译：氯法拉滨在中国小儿难治性或复发性急性淋巴细胞白血病中的疗效安全性和药代动力学：II期多中心研究
7. Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia [O] . Jeha, Sima, Razzouk, Bassem, Rytting, Michael, 2009

机译：小儿难治性或复发性急性髓细胞白血病患者的氯法拉滨二期研究

4118 Clofarabine: safety and efficacy profile for treatment of pediatric patients with refractory or relapsed acute leukemias

著录项

相似文献

相关主题

期刊订阅